Table 3.
Subanalysis of ulcer healing rates by CYP2C19 genotype and Helicobacter pylori serology (full analysis set)
| Keverprazan (n = 180) | Lansoprazole (n = 178) | P Value | |
| No. (%) of healed patients at week 6 | |||
| CYP2C19 genotype | |||
| Slow metabolizer | 20 (90.9) | 19 (90.5) | 1.0000 |
| Intermediate metabolizer | 74 (97.4) | 72 (91.1) | 0.1675 |
| Normal metabolizer | 74 (94.9) | 69 (98.6) | 0.3702 |
| Fast metabolizer | 1 (50.0) | 3 (75.0) | 1.0000 |
| Helicobacter pylori positive | 142 (94.0) | 145 (94.8) | 0.7814 |
| H. pylori negative | 28 (96.6) | 21 (84.0) | 0.1704 |
| No. (%) of healed patients at week 4 | |||
| CYP2C19 genotype | |||
| Slow metabolizer | 19 (86.4) | 17 (81.0) | 0.6981 |
| Intermediate metabolizer | 65 (85.5) | 62 (78.5) | 0.2544 |
| Normal metabolizer | 65 (83.3) | 59 (84.3) | 0.8753 |
| Fast metabolizer | 1 (50.0) | 3 (75.0) | 1.0000 |
| Helicobacter pylori positive | 126 (83.4) | 124 (81.1) | 0.5844 |
| H. pylori negative | 25 (86.2) | 19 (76.0) | 0.4852 |
CYP2C19 genotype data were missing in 2 and 4 patients for the keverprazan and lansoprazole group, respectively.